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ABSTRACT
Methods: A prospective, randomized, open, and parallel study was carried out in 100 patients attending the outpatient department of General 
Medicine Department MMIMSR, Mullana, Ambala, India with Stage -1 HTN according to joint national committee VII. The patients were randomly 
divided into two groups to receive Tab. Atenolol 50 mg od (Group A, n=50) and Tab. Olmesartan medoxomil 20 mg (Group B, n=50) od for a total period 
of 12 weeks with regular follow up every 2 weeks from the baseline. At each visit, blood pressure (BP), heart rate, and adverse effects were evaluated. 
Laboratory investigations were carried out at baseline and end of the study period. p<0.005 was considered statistically significant.
Results: Atenolol and Olmesartan medoxomil both significantly reduce BP and heart rate (p<0.005). Olmesartan medoxomil is more efficacious in 
reducing BP.
Conclusion: Olmesartan medoxomil is a better choice for Stage -1 HTN between the two drugs as it leads to a greater decrement in BP.
Keywords: Cardiovascular disease, Hypertension, Blood pressure, Systolic blood pressure, Diastolic blood pressure, Beta-blockers, Angiotensin 
receptor blockers, Heart rate.
INTRODUCTION
Cardiovascular disease (CVD) is one of the most common contributors 
of morbidity and mortality in underdeveloped and developing countries 
including South Asian countries including India [1]. The emergence 
of the CVD epidemic during the last three to four decades has been a 
very concerning cause for health-care providers in recent years [2]. 
Among the cluster group of CVDs, hypertension (HTN) represents the 
most common form of cardiovascular risk factor [3]. Several previous 
studies have demonstrated longitudinal associations between HTN 
and coronary artery disease, myocardial infarction [4]. HTN is defined 
as blood pressure (BP) of 140/90 mmHg or more on two separate 
occasions measured at least 1–2 weeks apart [5]. The prevalence of 
HTN increases with advancing age [5]. It affects approximately one-
third of the world’s adult population and it is predicted to increase 
by 60% toward 2025 [6]. HTN is also associated with several serious 
conditions and accounts for 13.5% of all premature deaths, 54% of 
all strokes, and 47% of ischemic heart diseases [7]. The number of 
adults with HTN in 2025 is predicted to exponentially increase by 
about 60% to a total of 1.56 billion [8]. Among all the hypertensive 
populations in developed countries and India, the percentage of those 
who are adequately controlled is estimated to be 50% and 11–12.8%, 
respectively [9]. CVDs caused 2.3 million deaths in India in the year 
1990; this is expected to double by the year 2020 [10]. HTN can be 
simply described as abnormal elevation in BP [11]. Primary HTN – with 
no obvious underlying medical causes [12] and secondary HTN – with 
identifiable cause [5]. According to joint national committee (JNC) 
VII in 2003, an increase in BP was again classified into three stages of 
HTN [5]. The JNC 8 classification for HTN and guideline management 
algorithm has been recently released in 2014 [13]. Another subtype of 
HTN includes isolated systolic HTN defined as a wide pulse pressure 
HTN resulting from excessive large artery stiffness [14]. Numerous 
common genetic variants with small effects on BP have been identified, 
for example, GUCY1A3-GUCY1B3 [15]. Several risk factors have been 
identified for the development of Primary or Essential HTN [16,17]. 
Diet: Micronutrients correlate with the prevalence of HTN and salt 
intake [18]. Inadequate intake of potassium, calcium, and magnesium 
has been implicated in the risk of HTN in various populations study 
but not in all trials [19,20]. Hyperlipidemia: Low high-density 
lipoprotein cholesterol and increased triglycerides are predictors of 
coronary artery heart diseases [21]. Obesity: 50% of obese patients 
have concomitant HTN [22] visceral obesity a strong risk factor for 
HTN [23- 25]. The relationship between obesity and HTN is observed 
virtually in all societies, ages [26]. Smoking: Smoking is an independent 
risk factor for cardiovascular deaths and stroke in females where risk 
is doubled [27]. Genetics: Genes have been implicated in the causation 
of high BP [28,29]. Aging: It has been found that BP increases with 
age, especially systolic BP (SBP) [30]. Type A personality: It has 
been well proven that type A personality has an increased risk of 
atherosclerosis and coronary morbidity [31]. Newer risk factors: 
Fibrinogen, hyperhomocysteinemia are new emerging factors of 
HTN [32-35]. About 30% of populations with hyperhomocysteinemia 
were found to have premature atherosclerosis [36]. Secondary HTN 
results from an identifiable underlying cause [37,38]. In most people 
with high BP, increased resistance to blood flow contributes to an 
elevation in BP level while heart rate remains normal [39]. Most 
evident implicates abnormalities in the intrarenal renin-Angiotensin-
aldosterone system [40,41]. Korotkoff described the systolic and 
diastolic sounds he heard with a stethoscope [42]. Janeway abandoned 
the clinical use of the term: essential HTN and called the disorder: 
hypertensive CVD [43]. Southern Medical Journal stated that: HTN is 
neither a cause of nephritis or arteriosclerosis [44]. The treatment of 
HTN itself is a difficult [45]. In 1950 despite the advances that occurred 
with the availability of Reserpine, Ganglionic blocking agents, limited 
the effectiveness [46]. Lowering BP in patients with HTN significantly 
decreased cardiovascular morbidity and mortality as compared with a 
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Objectives: The aim of the study was to compare the efficacy of Atenolol and Olmesartan in Stage-1 hypertension (HTN), and the adverse effect 
profile of Atenolol and Olmesartan in Stage-1 HTN.
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placebo-controlled trial [47]. The first JNC report was issued in 1977 
with updates occurring every 4–5 years [48]. In 2003, the JNC 7 report 
modified the previous JNC 6 guidelines and recommends a thiazide-
type diuretic as the preferred choice for initial monotherapy [49]. 
Lifestyle modifications complement to pharmacological therapy in 
lowering BP [50]. Diet control measures: The Diet Approach to Stop 
HTN trial showed a reduction in BP of 11.4/5.5 mm Hg [51]. Salt: There 
was a decrease of 4.8/2.5 mmhg in hypertensive patients [52,53]. 
Potassium: Potassium protects against vascular disease [54]. Calcium: 
The same inverse relationship has been shown with magnesium 
intake [55]. Calories and fat: Diets with fewer calories cause reductions 
in BP [56]. Alcohol: More than 3 drinks per day is a predictive cause for 
HTN [57]. Smoking: Smoking cessation decreases the risk of coronary 
artery [58]. Exercise: Sedentary individuals with normal BP have a 
20–50% increased risk of developing HTN [59]. Various drugs are 
available for treatment of HTN. Clinical trials have shown that thiazides 
in combination with other drugs have a synergistic effect [60,61]. The 
veteran’s affairs cooperative study class on antihypertensive agents has 
shown that the overall response rate in no responders was increased 
to 65% from 49% when combination therapy was used [62]. Beta-
blockers: Propranolol it revolutionized the medical management [63]. 
Atenolol is widely used for the management of HTN [64]. Angiotensin 
receptor blockers: All drugs in this class are approved by Food and Drug 
Administration for treatment of HTN, either alone or in combination 
with other drugs [65]. Olmesartan is a comparatively new Angiotensin 
II receptor antagonist used to treat HTN.
METHODS
A prospective, randomized, open, and parallel study was carried out in 
100 patients attending the outpatient department of General Medicine 
Department MMIMSR, Mullana, Ambala, India with Stage-1 HTN. 
The patients were randomly divided into two groups to receive Tab. 
Atenolol 50 mg od (Group A, n=50) and Tab. Olmesartan medoxomil 
20 mg (Group B, n=50) od for a total period of 12 weeks with regular 
follow-up every 2 weeks from the baseline.
RESULTS
Results were recorded and compared from the baseline. The results of 
the BP of individual patients were consolidated at the end of 12 weeks 
after treatment for both groups.
The analysis of Fig. 1 showed the average age of the patients treated with 
Atenolol 50 mg Drug was 43.10±7.78 years which was not significantly 
p>0.05 different than the average age of the patients treated under 
the Olmesartan 20 mg Drug, that is, 42.86±9.23. In the research study 
overall, 27–60 years of patients were considered and among them, 
28–60 years of patients were receiving the Atenolol 50 mg Drug, and 
the patients in the age group of 27–60 years were receiving Olmesartan 
20 mg Drug.
There were no statistical differences in context with baseline age 
characteristics between the two groups. The parameters were normally 
distributed and comparable (p-value>0.05).
The analysis of Fig. 2 showed in the research study 58.0% (58) were 
males and among them, 31 (62%) were receiving the Atenolol 50 mg 
Drug treatment, and 27 (54.0%) were receiving the Olmesartan 
20 mg drug treatment. Furthermore, there were 42.0% (42) of 
females were involved in the study and among them, 19 (38.0%) were 
receiving the Atenolol 50 mg drug treatment, and 23 (26.0%) were 
receiving the Olmesartan 20 mg drug treatment. The p-value obtained 
was >0.05 which shows that there is no significant difference in gender 
distribution of the two study groups.
The baseline means SBP of subjects in the Atenolol 50 mg drug 
group was 148.60 which significantly drops down to 143.12 at week 
2 assessment followed by again significant drops at each 2-week 
assessment and finally by the end of the 12-week assessment it 
significantly drops to 137.36. The baseline means SBP of subjects in 
the Olmesartan 20 mg drug group was 148.12 which significantly drops 
down to 138.28 at week 2 assessment followed by again significant 
drops at each 2-week assessment and finally by the end of the 12-week 
assessment it significantly dropped to 128.88.
It was further assessed that at baseline no significant difference was 
recorded among SBP levels among subjects of both drug groups but 
on comparative analysis at each week assessment shows that the 
Fig. 2: Gender Distribution of Subjects under Group A and 
Group B
Fig. 1: Comparison of the mean age of Group A and Group B
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subjects of Olmesartan 20 mg groups showed more decrease in SBP as 
compared to Atenolol 50 mg group subjects at baseline both subjects 
group Atenolol 50 mg and Olmesartan 20 mg had an average SBP of 
148.60 and 148.12, respectively, whereas at 12th-week assessment 
there was significant difference recorded as values of 137.36 and 
128.88, respectively.
The analysis of Fig. 4 showed that the overall reduction in SBP was 
more among the subjects under the drug group Olmesartan 20 mg, that 
is, 13.0% in the 12th week since the baseline recordings in comparison 
to the reduction in the same period for the subjects under the drug 
group Atenolol 50 mg, that is, 7.6%. Furthermore, it was analyzed that 
at each week’s assessment the percentage drop of SBP was evident 
more among the Olmesartan 20 mg group subjects in comparison to 
Atenolol 50 mg subjects.
The baseline means diastolic BP (DBP) of subjects in the Atenolol 50 mg 
drug group was 94.92 which significantly drops down to 91.68 at week 
2 assessment followed by a non-significant drop to 91.44 at the 4th-
week assessment of subjects but after that, at each 2-week assessment 
there was significant drop was recorded and finally, by the end of the 
12-week assessment it significantly dropped to 87.08.
The baseline mean DBP of subjects in the Olmesartan 20 mg drug group 
was 94.08 which significantly drops down to 88.04 at week 2 assessment 
and after that at each 2-week assessment there was significant drop 
was recorded and finally, by the end of the 12-week assessment, it 
significantly dropped to 81.24. It was further assessed that at baseline 
no significant difference was recorded among the DBP levels among the 
subjects of both drug groups but on comparative analysis at each week, 
the assessment shows that the subjects of Olmesartan 20 mg groups 
showed more decrease in DBP as compared to Atenolol 50 mg group 
subjects at baseline both subjects under group Atenolol 50 mg and 
Olmesartan 20 mg had average DBP of 94.92 and 94.08, respectively, 
whereas at 12th-week assessment there was significant difference 
recorded as values of 87.08 and 81.24, respectively.
The analysis of Fig. 5 showed that the overall reduction in DBP was 
more among the subjects under the drug group Olmesartan, that is, 
13.6% in the 12th week since the baseline recordings in comparison 
to the reduction in the same period for the subjects under the drug 
group Atenolol, that is, 8.3%. It was analyzed at most of the week 
assessment the percentage drop of DBP was almost similar among both 
drug groups, that is, weeks 6, 10, and 12 assessment whereas the larger 
difference was recorded at rest 3-week assessments.
The baseline means heart rate of subjects in the Atenolol 50 mg drug 
group was 85.72 which significantly drops down to 83.48 at week 2 
assessment followed by a significant drop at each 2-week assessment 
and finally by the end of the 12-week assessment it significantly 
dropped to 72.64.
The baseline means heart rate of subjects in Olmesartan 20 mg drug 
group was 86.72 which significantly drops down to 81.48 at week 6 
assessment but at 8th-week assessment, it was not significant drop, that 
is, 81.36 but after that, at each 2-week assessment there was significant 
drop was recorded and finally, by the end of the 12-week assessment, it 
significantly dropped to 78.88.
It was further assessed that at baseline no significant difference was 
recorded among the heart rate levels among the subjects of both drug 
groups as the subjects of Olmesartan 20 mg had a higher heart rate 
average than the subjects of Atenolol 50 mg subjects and on comparative 
analysis at each week assessment shows that the subjects of Olmesartan 
groups showed a lesser decrease in heart rate as compared to Atenolol 
50 mg group subjects at baseline both subjects group Atenolol 50 mg 
and Olmesartan 20 mg had average heart rate of 85.72 and 86.72 
respectively whereas at 12th-week assessment there was significant 
difference recorded as values of 72.64 and 78.88, respectively.
The analysis of Fig. 7 showed that the overall reduction in heart rate was 
more among the subjects under the drug group Atenolol 50 mg, that 
is, 15.3% in the 12th week since the baseline recordings in comparison 
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group Olmesartan 20 mg, that is, 9.0%. It was analyzed at all of the week 
assessment the percentage drop of heart rate was more among the 
Atenolol 50 mg group subjects but the opposite trend was only evident 
at 6th-week assessment when the subjects from the Olmesartan 20 mg 
showed more decrease in heart rate than the subjects from the Atenolol 
50 mg group.
The subjects of the Atenolol 50 mg group their average fasting blood 
sugar level at baseline time was 104.1 which decreased to 92.0 at the 
12th week of assessment whereas among the subject of the Olmesartan 
20 mg group their average fasting blood sugar level at baseline was 
105.6 but it drops down to 91.6 at the 12th-week assessment.
In the comparison of the two groups for the fasting blood sugar level, 
there was no significant difference was recorded at baseline and 
12th week between the fasting blood sugar of subjects measured. It was 
concluded that among the subjects of the Atenolol 50 mg group their 
fasting blood sugar level decreased by –8.9% from baseline to 12th-
week assessment while among the subjects of the Olmesartan 20 mg 
group it decreased by 9.0% in a similar time frame.
Fig. 9 describes the distribution of the subjects in terms of the adverse 
effect of drugs and it was analyzed that the neurological symptoms in 
Group A, 32.0% and 26.0% subjects reported headache and dizziness, 
respectively, while 16.0% and 36.0% of subjects reported the same in 
Group B, respectively.
DISCUSSION
Regarding baseline characteristics such as age distribution, there was 
no statistical difference (p>0.05) between the two groups. The Mean 
Age for Group A patients were43.10±7.78 years and Group B patients 
were 42.86±9.23 years, respectively. The age group selected for our 
study was 18–60 years. A similar age group was taken by Jackson 
et al. to see the effect of antihypertensive drugs (Atenolol, Ramipril, 
and Amlodipine) on lowering BP in hypertensive patients of age 
group 18–70 years for 3 years and no statistical difference (p>0.05) 
between two groups regarding age distribution [66].
While comparing other baseline characteristics such as gender 
distribution, the p-value obtained was >0.05 which shows that there is 
no significant difference in gender distribution of the two study groups. 
In our study, there were 31 males and 19 females in Group A and under 
the Group B category, there were 27 males and 23 females. In a study 
conducted by Rasmussen et al.. thirteen patients, of which nine men 
and four women were enrolled to do a comparison between effects of 
Atenolol and Metoprolol on BP and heart rate at rest, during exercise 
and there was no statistical difference (p>0.05) between two groups in 
context with gender distribution [67].
The parameters of our study were normally distributed and were 
comparable. One of the parameters of observations was SBP. The 
baseline means SBP of subjects in the Atenolol drug group was 148.60 
which significantly drops down to 143.12 at week 2 assessment 
followed by again significant drops at each 2-week assessment and 
finally by the end of the 12-week assessment it significantly drops 
to 137.36 an average reduction of 11.24 mmHg, while Freytag et al.. 
conducted a study to compare the efficacy as well as tolerability of 
Atenolol and Telmisartan in treatment of mild to moderate type of HTN 
in 489 patients for 26 weeks, they concluded that Final SBP reductions 
of 16.7 mmHg for the Atenolol, the difference in SBP was significant 
(p<0.005). When we compared the results of these studies, we found 
that there is a greater reduction of SBP, that is, 16.7 mmHg in Freytag 
et al.. than our study, that is, 11.24 mmHg [68].
The baseline means SBP of subjects in the Olmesartan drug group was 
148.12 which significantly drops down to 138.28 at week 2 assessment 
followed by again significant drops at each 2-week assessment and 
finally by the end of the 12-week assessment it significantly dropped 
to 128.88, that is, an average reduction of 19.24 mmHg. A similar 
double-blind study was conducted by Van Miegham to compare the 
efficacy of Olmesartan 20 mg (n=165) and Atenolol 50 mg (n=161) for 
12 weeks. They concluded that a significantly greater reduction in SBP 
was observed from baseline with Olmesartan (–20.7±1.0) than with 
Atenolol (–17.2±1.0). When we compared the results of these studies, 
we found that a reduction of 20.7 mmHg of SBP was observed in the Van 
Miegham study, while a reduction of 19.24 mmHg was observed in our 
study, and results are almost coinciding with each other [69].
The baseline means DBP of subjects in the Atenolol drug group was 
94.92 which significantly drops down to 91.68 at week 2 assessment 
followed by a non-significant drop to 91.44 at the 4th-week assessment 
of subjects but after that, at each 2-week assessment there was a 
significant drop was recorded and finally, by the end of the 12-week 
assessment it significantly dropped to 87.08, thus there is a significant 
decrease of 7.84 mmHg (p<0.001). Alcocer et al.. conducted an open-
label, parallel-group comparative study to analyze the clinical efficacy 
and safety of Atenolol 50 mg and Telmisartan 80 mg on systolic and 
DBP in 58 patients with mild to moderate HTN and concluded that there 
was a significant decrease in DBP of 10.1 mmHg versus 14.7 mmHg. 
When we compared the results of these studies, we found that greater 
reduction of DBP, that is, 10.1 mmHg in the Alcocer et al.. study than our 
study, that is, 7.84 mmHg [70].
The baseline mean DBP of subjects in the Olmesartan drug group was 
94.08 which significantly drops down to 88.04 at week 2 assessment 
and after that, at each 2-week assessment there was significant drop 
was recorded and finally, by the end of the 12-week assessment, 
it significantly drops to 81.24, thus there is the final reduction of 
12.84 mmHg. Puchler et al.. conducted a double-blind study on 
328 patients with moderate to severe type HTN mean sitting DBP 
of 100 to 120 mmHg receiving 25 mg of hydrochlorothiazide daily 














































Fig. 9: Bar Chart Comparison of adverse drug reactions among 
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plus HCTZ or Atenolol (50 mg) once daily plus HCTZ for 12 weeks and 
they concluded that mean reduction in DBP from the baseline were 
similar for Olmesartan group (–17.3±6.3 mmhg) and the Atenolol group 
(–17.2±6.4 mmHg) in patients receiving either Olmesartan (10 mg) 
once daily plus HCTZ or Atenolol (50 mg) once daily plus HCTZ for 
12 weeks. When we compared the results of these studies, we found 
that there is a reduction of 17.3 mmHg of DBP in the Puchler et al.. 
study while there is a lesser reduction of DBP, that is, 12.84 mmHg in 
our study. The greater reduction may be due to the addition of HCTZ as 
an antihypertensive drug in this study [71].
The heart rates in Group A (Atenolol). The baseline means heart rate 
of subjects in the Atenolol drug group was 85.72 which significantly 
drops down to 83.48 at week 2 assessment followed by a significant 
drop at each 2-week assessment and finally by the end of the 12-week 
assessment it significantly dropped to 72.64, counting for an average 
reduction of 13.08 beats/min. While Pollare et al.. conducted a study on 
sixty patients with primary HTN and studied the effects of Atenolol and 
Metoprolol and concluded that there is a significant reduction in heart 
rate, 9 beats/min in the supine position after medication, which was 
similar for Atenolol and Metoprolol. When we compared the results of 
these studies, we found that heart rate was decreased significantly in 
both of these studies but a greater reduction in heart rate was observed 
in our study, that is, 13.08 beats/min as compared to 9 beats/min in 
Pollare et al.. study [72].
In Group B (Olmesartan), the baseline means Heart Rate of subjects 
in the Olmesartan drug group was 86.72 which significantly drops 
down to 81.48 at week 6 assessment but at 8th week assessment, it 
was not significant drop, that is, 81.36 but after that, at each 2-week 
assessment there was significant drop was recorded and finally, by 
the end of the 12-week assessment, it was significant drops to 78.88, 
that is, an average reduction of 7.8 beats/min. A fine comparative 
study conducted by Rasmussen et al.. on 13 patients (nine men and 
four women, aged 37–67 years) with mild/moderate essential HTN 
to do a comparison between Atenolol and Metoprolol 50, 100, and 
200 mg doses given once daily on BP, and concluded that significant 
(p<0.001) reduction of 12 beats/min in heart rate in test situations 
were observed with 50 mg Atenolol [67]. While Sahana et al.. studied 
the effect of-Atenolol 50 mg once daily versus Nebivolol 5 mg once daily 
(S) in patients with essential HTN and concluded that fall in heart rate 
was significant (p<0.0001) by 11 beats/min at the end of the 1st, 2nd, 
and 3rd month when compared to baseline by Atenolol 50 mg therapy. 
When we compared our results with these studies we concluded that 
although Olmesartan is reducing heart significantly by 7.8 beats/min 
Atenolol is found to be more significantly reducing the heart rate by 12 
beats/min in Rasmussen et al.. study and 11 beats/min in Sahana et al.. 
studies [67,73].
Fasting blood sugar level among Group A (Atenolol) patients at 
baseline was 104.1±14.2 mg/dl which non-significantly decreased to 
92.0±12.9 mg/dl, that is, it reduces by 8.9%. In Group B, (Olmesartan) 
subject’s baseline Fasting blood sugar level was observed to be 
105.6±15.3 mg/dl which non significantly reduces by 9.0% to 
91.6±13.0 mg/dl at the end of 12 weeks of therapy. Fonseca reviewed 
the pathophysiology of HTN and evaluated the effects from glucose by 
beta-blockers, namely, Atenolol, Metoprolol, Propranolol and concluded 
that beta-blockers have favorable effects on glucose metabolism [74]. 
This study is coinciding with my study. Smith et al.. evaluated Atenolol 
effects in men with type 2 diabetes mellitus during cardio respiratory 
exercise in both fasting and postprandial glucose and demonstrates 
that Atenolol decreased fasting and postprandial glucose (p<0.001). 
This study differs from my study, thus to confirm effects on fasting 
blood sugar, more studies are to be done [75].
During treatment, adverse effects were reported by the patients of both 
Groups. It was analyzed that the neurological symptoms headache and 
dizziness in Group A are 32.0% and 26.0% in subjects, respectively, while 
16.0% and 36.0% in subjects in Group B, respectively. Gastrointestinal 
symptoms nausea, vomiting, and diarrhea reported in Group A are 
28.0% and 24.0% in subjects, respectively, while 16.0% and 8.0% in 
subjects reported the same in Group B, respectively.
About 26.0% of subjects in Group A reported hypotension while 28.0% 
reported fatigue on contrary in Group B 16.0% of subjects reported 
hypotension and 4.0% reported fatigue. Van Miegham conducted a 
double-blind study on 326 patients who are randomly assigned to 
receive either Olmesartan 20 mg once daily or Atenolol once daily for 
12 weeks and concluded that both Olmesartan and Atenolol were well 
tolerated and adverse effects reported were minimal and were non-
significant (p>0.001). Thus, in terms of adverse effects, my study is 
coinciding with this study [69].
CONCLUSION
Olmesartan is a better choice for the treatment of Stage I hypertensive 
patients because of a greater reduction in BP. The lesser decrement of 
heart rate with Olmesartan indicates its preferred use in end-organ 
failure clinical conditions. The fewer incidences of adverse events with 
Olmesartan than Atenolol indicate a better safety profile.
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